Clinical Trial Update: Niraparib + Dostarlimab + RT in Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results of Niraparib plus Dostarlimab with radiotherapy in pancreatic cancer have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-07-03